Prudential Financial Inc. Decreases Stake in Ikena Oncology, Inc. (NASDAQ:IKNA)

Prudential Financial Inc. cut its holdings in shares of Ikena Oncology, Inc. (NASDAQ:IKNA) by 38.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 18,200 shares of the company’s stock after selling 11,600 shares during the quarter. Prudential Financial Inc.’s holdings in Ikena Oncology were worth $30,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of IKNA. FMR LLC lifted its stake in Ikena Oncology by 94.1% during the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock valued at $66,000 after acquiring an additional 18,607 shares during the period. Geode Capital Management LLC grew its stake in shares of Ikena Oncology by 5.6% in the third quarter. Geode Capital Management LLC now owns 271,026 shares of the company’s stock worth $469,000 after acquiring an additional 14,319 shares during the period. Peapod Lane Capital LLC purchased a new position in shares of Ikena Oncology during the fourth quarter valued at approximately $833,000. Finally, BML Capital Management LLC lifted its position in Ikena Oncology by 395.8% during the fourth quarter. BML Capital Management LLC now owns 3,585,866 shares of the company’s stock valued at $5,881,000 after purchasing an additional 2,862,578 shares during the period. 75.00% of the stock is currently owned by institutional investors.

Ikena Oncology Stock Performance

Shares of NASDAQ:IKNA opened at $1.10 on Friday. The stock’s 50-day simple moving average is $1.33 and its two-hundred day simple moving average is $1.54. The stock has a market capitalization of $53.08 million, a price-to-earnings ratio of -0.89 and a beta of 0.48. Ikena Oncology, Inc. has a 52-week low of $0.97 and a 52-week high of $1.94.

Ikena Oncology (NASDAQ:IKNA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. As a group, equities analysts forecast that Ikena Oncology, Inc. will post -0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wedbush reiterated a “neutral” rating and set a $2.00 target price on shares of Ikena Oncology in a research note on Monday, December 23rd.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.